184 related articles for article (PubMed ID: 20160209)
1. Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy.
Yamada TH; Denburg NL; Beglinger LJ; Schultz SK
J Neuropsychiatry Clin Neurosci; 2010; 22(1):48-54. PubMed ID: 20160209
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy.
Jim HS; Phillips KM; Chait S; Faul LA; Popa MA; Lee YH; Hussin MG; Jacobsen PB; Small BJ
J Clin Oncol; 2012 Oct; 30(29):3578-87. PubMed ID: 22927526
[TBL] [Abstract][Full Text] [Related]
3. Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer.
Reid-Arndt SA; Hsieh C; Perry MC
Psychooncology; 2010 May; 19(5):535-44. PubMed ID: 19472296
[TBL] [Abstract][Full Text] [Related]
4. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.
Ahles TA; Saykin AJ; Furstenberg CT; Cole B; Mott LA; Skalla K; Whedon MB; Bivens S; Mitchell T; Greenberg ER; Silberfarb PM
J Clin Oncol; 2002 Jan; 20(2):485-93. PubMed ID: 11786578
[TBL] [Abstract][Full Text] [Related]
5. Cognitive deficits in Korean women treated with chemotherapy for breast cancer.
Jung MS; Cimprich B
Cancer Nurs; 2014; 37(3):E31-42. PubMed ID: 23945143
[TBL] [Abstract][Full Text] [Related]
6. Cognitive features 10 or more years after successful breast cancer survival: comparisons across types of cancer interventions.
Nguyen CM; Yamada TH; Beglinger LJ; Cavanaugh JE; Denburg NL; Schultz SK
Psychooncology; 2013 Apr; 22(4):862-8. PubMed ID: 22585465
[TBL] [Abstract][Full Text] [Related]
7. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy.
Mehnert A; Scherwath A; Schirmer L; Schleimer B; Petersen C; Schulz-Kindermann F; Zander AR; Koch U
Patient Educ Couns; 2007 Apr; 66(1):108-18. PubMed ID: 17320337
[TBL] [Abstract][Full Text] [Related]
8. Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction?
Ganz PA; Bower JE; Kwan L; Castellon SA; Silverman DH; Geist C; Breen EC; Irwin MR; Cole SW
Brain Behav Immun; 2013 Mar; 30 Suppl(Suppl):S99-108. PubMed ID: 22884417
[TBL] [Abstract][Full Text] [Related]
9. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer.
Hermelink K
Cancer; 2011 Mar; 117(5):1103; author reply 1103-4. PubMed ID: 20960507
[No Abstract] [Full Text] [Related]
10. Assessing cognitive dysfunction in breast cancer: what are the tools?
Freeman JR; Broshek DK
Clin Breast Cancer; 2002 Dec; 3 Suppl 3():S91-9. PubMed ID: 12533269
[TBL] [Abstract][Full Text] [Related]
11. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy.
Ahles TA; Saykin AJ; Noll WW; Furstenberg CT; Guerin S; Cole B; Mott LA
Psychooncology; 2003 Sep; 12(6):612-9. PubMed ID: 12923801
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors.
Kesler SR; Blayney DW
JAMA Oncol; 2016 Feb; 2(2):185-92. PubMed ID: 26633037
[TBL] [Abstract][Full Text] [Related]
13. Lifestyle factors associated with cognitive functioning in breast cancer survivors.
Hartman SJ; Marinac CR; Natarajan L; Patterson RE
Psychooncology; 2015 Jun; 24(6):669-75. PubMed ID: 25073541
[TBL] [Abstract][Full Text] [Related]
14. Cognitive functioning after cancer treatment: a 3-year longitudinal comparison of breast cancer survivors treated with chemotherapy or radiation and noncancer controls.
Phillips KM; Jim HS; Small BJ; Laronga C; Andrykowski MA; Jacobsen PB
Cancer; 2012 Apr; 118(7):1925-32. PubMed ID: 22161750
[TBL] [Abstract][Full Text] [Related]
15. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study.
Stewart A; Collins B; Mackenzie J; Tomiak E; Verma S; Bielajew C
Psychooncology; 2008 Feb; 17(2):122-30. PubMed ID: 17518411
[TBL] [Abstract][Full Text] [Related]
16. 'Chemobrain' in breast carcinoma?: a prologue.
Wefel JS; Lenzi R; Theriault R; Buzdar AU; Cruickshank S; Meyers CA
Cancer; 2004 Aug; 101(3):466-75. PubMed ID: 15274059
[TBL] [Abstract][Full Text] [Related]
17. Relationship between chemotherapy use and cognitive impairments in older women with breast cancer: findings from a large population-based cohort.
Du XL; Xia R; Hardy D
Am J Clin Oncol; 2010 Dec; 33(6):533-43. PubMed ID: 20023570
[TBL] [Abstract][Full Text] [Related]
18. Selective impairment of attention networks in breast cancer patients receiving chemotherapy treatment.
Chen X; Li J; Ren J; Hu X; Zhu C; Tian Y; Hu P; Ma H; Yu F; Wang K
Psychooncology; 2014 Oct; 23(10):1165-71. PubMed ID: 24737580
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy.
Koppelmans V; Breteler MM; Boogerd W; Seynaeve C; Gundy C; Schagen SB
J Clin Oncol; 2012 Apr; 30(10):1080-6. PubMed ID: 22370315
[TBL] [Abstract][Full Text] [Related]
20. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy.
O'Shaughnessy JA
Clin Breast Cancer; 2002 Dec; 3 Suppl 3():S116-20. PubMed ID: 12533272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
